ReviewCancers2021

Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?

Takaaki OnoPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.